Published in Pharmacol Rev on June 07, 2012
The Concise Guide to PHARMACOLOGY 2013/14: enzymes. Br J Pharmacol (2013) 5.57
Adverse drug reactions and drug-drug interactions with over-the-counter NSAIDs. Ther Clin Risk Manag (2015) 0.96
Decidual Cox2 inhibition improves fetal and maternal outcomes in a preeclampsia-like mouse model. JCI Insight (2016) 0.85
Altered matrix metalloproteinase-2 and -9 expression/activity links placental ischemia and anti-angiogenic sFlt-1 to uteroplacental and vascular remodeling and collagen deposition in hypertensive pregnancy. Biochem Pharmacol (2014) 0.83
Enhanced endothelin receptor type B-mediated vasodilation and underlying [Ca²⁺]i in mesenteric microvessels of pregnant rats. Br J Pharmacol (2013) 0.82
EMMPRIN-mediated induction of uterine and vascular matrix metalloproteinases during pregnancy and in response to estrogen and progesterone. Biochem Pharmacol (2013) 0.81
Enhanced serelaxin signalling in co-cultures of human primary endothelial and smooth muscle cells. Br J Pharmacol (2016) 0.81
A cyclooxygenase-2-dependent prostaglandin E2 biosynthetic system in the Golgi apparatus. J Biol Chem (2014) 0.80
Vascular actions of relaxin: nitric oxide and beyond. Br J Pharmacol (2016) 0.79
1-methylnicotinamide and its structural analog 1,4-dimethylpyridine for the prevention of cancer metastasis. J Exp Clin Cancer Res (2016) 0.78
Prenatal effects of maternal consumption of polyphenol-rich foods in late pregnancy upon fetal ductus arteriosus. Birth Defects Res C Embryo Today (2013) 0.77
Matrix Metalloproteinases as Regulators of Vein Structure and Function: Implications in Chronic Venous Disease. J Pharmacol Exp Ther (2015) 0.76
Plasma arachidonic and docosahexaenoic acids in Tunisian very low birth weight infants: status and association with selected neonatal morbidities. J Health Popul Nutr (2015) 0.75
Affinin (Spilanthol), Isolated from Heliopsis longipes, Induces Vasodilation via Activation of Gasotransmitters and Prostacyclin Signaling Pathways. Int J Mol Sci (2017) 0.75
rs5911 and rs3842788 Genetic Polymorphism, Blood Stasis Syndrome, and Plasma TXB2 and hs-CRP Levels Are Associated with Aspirin Resistance in Chinese Chronic Stable Angina Patients. Evid Based Complement Alternat Med (2017) 0.75
Matrix Metalloproteinases in Remodeling of Lower Extremity Veins and Chronic Venous Disease. Prog Mol Biol Transl Sci (2017) 0.75
Microglial TNFα Induces COX2 and PGI2 Synthase Expression in Spinal Endothelial Cells during Neuropathic Pain. eNeuro (2017) 0.75
Mechanisms of Endothelial Dysfunction in Hypertensive Pregnancy and Preeclampsia. Adv Pharmacol (2016) 0.75
Genetic, immune and vasoactive factors in the vascular dysfunction associated with hypertension in pregnancy. Expert Opin Ther Targets (2015) 0.75
Decreased Homodimerization and Increased TIMP-1 Complexation of Uteroplacental and Uterine Arterial Matrix Metalloproteinase-9 during Hypertension-in-Pregnancy. Biochem Pharmacol (2017) 0.75
Genetic variants of PTGS2, TXA2R and TXAS1 are associated with carotid plaque vulnerability, platelet activation and TXA2 levels in ischemic stroke patients. PLoS One (2017) 0.75
Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia. Prog Mol Biol Transl Sci (2017) 0.75
Increased Vascular and Uteroplacental Matrix Metalloproteinase-1 and -7 Levels and Collagen I Deposition in Hypertension-in-Pregnancy. Role of TNF. Am J Physiol Heart Circ Physiol (2017) 0.75
Prostaglandins and leukotrienes: advances in eicosanoid biology. Science (2001) 11.23
Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem (2000) 8.86
Prostanoid receptors: structures, properties, and functions. Physiol Rev (1999) 8.60
Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A (1997) 7.52
Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol (1998) 7.22
Role of prostacyclin in the cardiovascular response to thromboxane A2. Science (2002) 4.59
Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev (2004) 4.41
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A (1999) 4.16
Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther (2004) 3.40
Patent ductus arteriosus. Circulation (2006) 3.22
Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature (1997) 3.07
Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol (2002) 2.84
Thematic Review Series: Proteomics. An integrated omics analysis of eicosanoid biology. J Lipid Res (2009) 2.71
Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol (2010) 2.43
The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol (1996) 2.43
Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci (2004) 2.40
The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am J Obstet Gynecol (1997) 2.40
Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. JAMA (1999) 2.34
Role of the placenta in fetal programming: underlying mechanisms and potential interventional approaches. Clin Sci (Lond) (2007) 2.23
Patent ductus arteriosus of the preterm infant. Pediatrics (2010) 2.10
Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev (2007) 2.07
Angiogenic function of prostacyclin biosynthesis in human endothelial progenitor cells. Circ Res (2008) 1.87
Prostaglandins PGE(2) and PGI(2) promote endothelial barrier enhancement via PKA- and Epac1/Rap1-dependent Rac activation. Exp Cell Res (2007) 1.83
Tocolytic therapy: a meta-analysis and decision analysis. Obstet Gynecol (2009) 1.82
Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther (2006) 1.78
Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation (2002) 1.78
The pharmacology of the ductus arteriosus. Pharmacol Rev (1998) 1.66
Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J Clin Invest (1999) 1.59
Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator-activated receptors. J Mol Cell Cardiol (2004) 1.59
Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat (2002) 1.58
Prostacyclin/thromboxane early changes in pregnancies that are complicated by preeclampsia. Am J Obstet Gynecol (2003) 1.57
The diagnosis, management, and postnatal prevention of intraventricular hemorrhage in the preterm neonate. Clin Perinatol (2008) 1.50
Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration. Crit Care Med (2003) 1.49
Analysis of nonsteroidal antiinflammatory drugs in meconium and its relation to persistent pulmonary hypertension of the newborn. Pediatrics (2001) 1.45
Impact of TASK-1 in human pulmonary artery smooth muscle cells. Circ Res (2006) 1.44
Multicentre trial of ethamsylate for prevention of periventricular haemorrhage in very low birthweight infants. Lancet (1986) 1.40
Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated cAMP generation. J Biol Chem (2004) 1.38
Placental isoprostane is significantly increased in preeclampsia. FASEB J (2000) 1.38
Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol (2009) 1.31
Prostacyclin-induced vasodilation in rabbit heart is mediated by ATP-sensitive potassium channels. Am J Physiol (1993) 1.29
Importance of endothelium-derived hyperpolarizing factor in human arteries. J Clin Invest (1997) 1.29
Chronic activation of the prostaglandin receptor EP4 promotes hyaluronan-mediated neointimal formation in the ductus arteriosus. J Clin Invest (2006) 1.29
Prophylactic intravenous indomethacin for preventing mortality and morbidity in preterm infants. Cochrane Database Syst Rev (2010) 1.29
Prostaglandin receptor signaling in disease. ScientificWorldJournal (2007) 1.26
Prostaglandin H synthase and vascular function. Circ Res (2001) 1.23
Alteration of flow-induced dilatation in mesenteric resistance arteries of L-NAME treated rats and its partial association with induction of cyclo-oxygenase-2. Br J Pharmacol (1997) 1.23
The structures of prostaglandin endoperoxide H synthases-1 and -2. Prostaglandins Other Lipid Mediat (2002) 1.22
Coordinated regulation of fetal and maternal prostaglandins directs successful birth and postnatal adaptation in the mouse. Proc Natl Acad Sci U S A (2000) 1.22
Intervention strategies for neonatal hypoxic-ischemic cerebral injury. Clin Ther (2006) 1.22
Acetylcholine-induced endothelium-dependent contractions in the SHR aorta: the Janus face of prostacyclin. Br J Pharmacol (2005) 1.21
Oxidants, nitric oxide and prostanoids in the developing ocular vasculature: a basis for ischemic retinopathy. Cardiovasc Res (2000) 1.20
Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. Pharmacol Ther (2010) 1.20
Congenital malformations in offspring of diabetic mothers--animal and human studies. Rev Endocr Metab Disord (2003) 1.20
Prostaglandins in health and disease: an overview. Semin Arthritis Rheum (2006) 1.18
Phospholipase A2 inhibitors as potential anti-inflammatory agents. Curr Pharm Des (2005) 1.18
Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy. Circulation (2003) 1.16
Peroxynitrite and protein tyrosine nitration of prostacyclin synthase. Prostaglandins Other Lipid Mediat (2006) 1.15
Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J Pediatr (2002) 1.15
Eicosanoids in preeclampsia. Prostaglandins Leukot Essent Fatty Acids (2004) 1.15
Prostaglandin D2 protects neonatal mouse brain from hypoxic ischemic injury. J Neurosci (2007) 1.14
Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke. Am J Respir Crit Care Med (2007) 1.13
Uterine vascular function in a transgenic preeclampsia rat model. Hypertension (2008) 1.12
The onset of breathing at birth stimulates pulmonary vascular prostacyclin synthesis. Pediatr Res (1984) 1.12
Intrauterine growth restriction: fetal programming of hypertension and kidney disease. Adv Chronic Kidney Dis (2008) 1.11
Prostanoid receptor subtypes. Prostaglandins Other Lipid Mediat (2002) 1.11
Emerging roles of secreted phospholipase A2 enzymes: Lessons from transgenic and knockout mice. Biochimie (2010) 1.10
Prostacyclin among prostanoids. Pharmacol Rep (2008) 1.10
A novel pathway of prostacyclin signaling-hanging out with nuclear receptors. Endocrinology (2002) 1.10
RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists. Br J Pharmacol (2006) 1.08
Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. Am J Respir Cell Mol Biol (2005) 1.08
Effects of aspirin consumption during pregnancy on pregnancy outcomes: meta-analysis. Birth Defects Res B Dev Reprod Toxicol (2003) 1.08
Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol Ther (2008) 1.07
The second PGD(2) receptor CRTH2: structure, properties, and functions in leukocytes. Prostaglandins Leukot Essent Fatty Acids (2003) 1.07
Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. Atherosclerosis (2008) 1.05
Vasodilator factors in the systemic and local adaptations to pregnancy. Reprod Biol Endocrinol (2009) 1.05
Pathophysiologic mechanisms of persistent pulmonary hypertension of the newborn. Pediatr Pulmonol (2005) 1.05
Prostaglandin synthases: recent developments and a novel hypothesis. Prostaglandins Leukot Essent Fatty Acids (2004) 1.04
Phenotypes of the COX-deficient mice indicate physiological and pathophysiological roles for COX-1 and COX-2. Prostaglandins Other Lipid Mediat (2002) 1.04
Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension. Drugs (2002) 1.04
Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clin Pharmacol Ther (2007) 1.04
Cardioprotective prostacyclin signaling in vascular smooth muscle. Prostaglandins Other Lipid Mediat (2006) 1.04
Prostanoid receptors: ontogeny and implications in vascular physiology. Am J Physiol Regul Integr Comp Physiol (2001) 1.03
Cyclooxygenase-1-selective inhibition prolongs gestation in mice without adverse effects on the ductus arteriosus. J Clin Invest (2002) 1.03
Increased phospholipase A2 and thromboxane but not prostacyclin production by placental trophoblast cells from normal and preeclamptic pregnancies cultured under hypoxia condition. Placenta (2005) 1.03
Prostanoid receptors involved in the relaxation of human pulmonary vessels. Br J Pharmacol (1999) 1.02
Prostacyclin in vascular diseases. - Recent insights and future perspectives -. Circ J (2010) 1.02
Characterization of dilator prostanoid receptors in the fetal rabbit ductus arteriosus. J Pharmacol Exp Ther (1994) 1.02
New insights into the retinal circulation: inflammatory lipid mediators in ischemic retinopathy. Prostaglandins Leukot Essent Fatty Acids (2005) 1.02
Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritis. J Pharmacol Exp Ther (2006) 1.02
Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia. Cardiovasc Hematol Agents Med Chem (2010) 1.02
Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins. Br J Pharmacol (2001) 1.01
From the design to the clinical application of thromboxane modulators. Curr Pharm Des (2006) 1.01
Induction of prostacyclin/PGI2 synthase expression after cerebral ischemia-reperfusion. J Cereb Blood Flow Metab (2006) 1.01
Colocalization of prostacyclin synthase with prostaglandin H synthase-1 (PGHS-1) but not phorbol ester-induced PGHS-2 in cultured endothelial cells. J Biol Chem (2000) 1.01
Cyclooxygenase-1 and bicistronic cyclooxygenase-1/prostacyclin synthase gene transfer protect against ischemic cerebral infarction. Circulation (2002) 1.00
Endothelin-1 releases prostacyclin and inhibits ex vivo platelet aggregation in the anesthetized rabbit. J Cardiovasc Pharmacol (1989) 1.00
Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol (2007) 3.19
Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol (2009) 3.05
Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol (2004) 2.58
Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. Microcirculation (2002) 1.78
Interleukin-6 impairs endothelium-dependent NO-cGMP-mediated relaxation and enhances contraction in systemic vessels of pregnant rats. Am J Physiol Regul Integr Comp Physiol (2004) 1.71
Protein kinase C isoforms as specific targets for modulation of vascular smooth muscle function in hypertension. Biochem Pharmacol (2005) 1.52
Role of oxidative stress in age-related reduction of NO-cGMP-mediated vascular relaxation in SHR. Am J Physiol Regul Integr Comp Physiol (2003) 1.51
Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease. Biochem Pharmacol (2012) 1.25
The vascular endothelin system in hypertension--recent patents and discoveries. Recent Pat Cardiovasc Drug Discov (2006) 1.16
Sex difference in cardiovascular risk: role of pulse pressure amplification. J Am Coll Cardiol (2012) 1.15
Matrix metalloproteinase 2-induced venous dilation via hyperpolarization and activation of K+ channels: relevance to varicose vein formation. J Vasc Surg (2007) 1.11
Effect of dietary sodium on vasoconstriction and eNOS-mediated vascular relaxation in caveolin-1-deficient mice. Am J Physiol Heart Circ Physiol (2008) 1.11
Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction. J Vasc Surg (2004) 1.09
Gender differences in the regulation of vascular tone. Clin Exp Pharmacol Physiol (2003) 1.08
Cellular mediators of renal vascular dysfunction in hypertension. Am J Physiol Regul Integr Comp Physiol (2009) 1.08
Reduced endothelial vascular relaxation in growth-restricted offspring of pregnant rats with reduced uterine perfusion. Hypertension (2003) 1.06
Sensitivity of NOS-dependent vascular relaxation pathway to mineralocorticoid receptor blockade in caveolin-1-deficient mice. Am J Physiol Heart Circ Physiol (2010) 1.05
Sex steroids and vascular responses in hypertension and aging. Gend Med (2008) 1.04
Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. EXS (2012) 1.03
Prolonged increases in vein wall tension increase matrix metalloproteinases and decrease constriction in rat vena cava: Potential implications in varicose veins. J Vasc Surg (2008) 1.02
Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia. Cardiovasc Hematol Agents Med Chem (2010) 1.02
Estrogenic compounds, estrogen receptors and vascular cell signaling in the aging blood vessels. Curr Med Chem (2009) 1.01
Endothelin-1--induced enhancement of coronary smooth muscle contraction via MAPK-dependent and MAPK-independent [Ca(2+)](i) sensitization pathways. Hypertension (2002) 1.01
Increased vascular angiotensin type 2 receptor expression and NOS-mediated mechanisms of vascular relaxation in pregnant rats. Am J Physiol Heart Circ Physiol (2009) 1.00
Reduced endothelial NO-cGMP vascular relaxation pathway during TNF-alpha-induced hypertension in pregnant rats. Am J Physiol Regul Integr Comp Physiol (2002) 0.99
Age-related reduction in estrogen receptor-mediated mechanisms of vascular relaxation in female spontaneously hypertensive rats. Hypertension (2003) 0.99
Prolonged mechanical stretch is associated with upregulation of hypoxia-inducible factors and reduced contraction in rat inferior vena cava. J Vasc Surg (2010) 0.97
Pathophysiology of essential hypertension: role of the pump, the vessel, and the kidney. Semin Nephrol (2002) 0.96
Dissociation of hyperglycemia from altered vascular contraction and relaxation mechanisms in caveolin-1 null mice. J Pharmacol Exp Ther (2013) 0.95
Gender-specific reduction in contraction is associated with increased estrogen receptor expression in single vascular smooth muscle cells of female rat. Cell Physiol Biochem (2010) 0.95
Endothelin-1 promotes Ca2+ antagonist-insensitive coronary smooth muscle contraction via activation of epsilon-protein kinase C. Hypertension (2004) 0.94
Histone demethylase LSD1 deficiency during high-salt diet is associated with enhanced vascular contraction, altered NO-cGMP relaxation pathway, and hypertension. Am J Physiol Heart Circ Physiol (2011) 0.94
Matrix metalloproteinases in venous tissue remodeling and varicose vein formation. Curr Vasc Pharmacol (2008) 0.93
Impact of sex hormone metabolism on the vascular effects of menopausal hormone therapy in cardiovascular disease. Curr Drug Metab (2010) 0.92
Impaired vasoconstriction and nitric oxide-mediated relaxation in pulmonary arteries of hypoxia- and monocrotaline-induced pulmonary hypertensive rats. J Pharmacol Exp Ther (2009) 0.91
Subtype-specific estrogen receptor-mediated vasodilator activity in the cephalic, thoracic, and abdominal vasculature of female rat. J Cardiovasc Pharmacol (2013) 0.91
Sex hormone replacement therapy and modulation of vascular function in cardiovascular disease. Expert Rev Cardiovasc Ther (2007) 0.90
Endothelin-induced increases in Ca2+ entry mechanisms of vascular contraction are enhanced during high-salt diet. Hypertension (2002) 0.88
Neurovascular mechanisms of hypertension in pregnancy. Curr Neurovasc Res (2006) 0.88
TNF-alpha enhances contraction and inhibits endothelial NO-cGMP relaxation in systemic vessels of pregnant rats. Am J Physiol Regul Integr Comp Physiol (2002) 0.88
Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins. Curr Drug Targets (2013) 0.87
Risk factors and mediators of the vascular dysfunction associated with hypertension in pregnancy. Cardiovasc Hematol Disord Drug Targets (2010) 0.87
MMP-2 induced vein relaxation via inhibition of [Ca2+]e-dependent mechanisms of venous smooth muscle contraction. Role of RGD peptides. J Surg Res (2008) 0.87
Reduced endothelial NO-cGMP-mediated vascular relaxation and hypertension in IL-6-infused pregnant rats. Hypertension (2004) 0.86
Estrogen receptor-mediated enhancement of venous relaxation in female rat: implications in sex-related differences in varicose veins. J Vasc Surg (2010) 0.86
Decreased endothelium-dependent NO-cGMP vascular relaxation and hypertension in growth-restricted rats on a high-salt diet. Hypertension (2004) 0.86
Vascular effects of estrogenic menopausal hormone therapy. Rev Recent Clin Trials (2012) 0.85
Modulators of vascular sex hormone receptors and their effects in estrogen-deficiency states associated with menopause. Recent Pat Cardiovasc Drug Discov (2008) 0.85
Enhanced [Ca2+]i in renal arterial smooth muscle cells of pregnant rats with reduced uterine perfusion pressure. Am J Physiol Heart Circ Physiol (2002) 0.85
Increased MMPs expression and decreased contraction in the rat myometrium during pregnancy and in response to prolonged stretch and sex hormones. Am J Physiol Endocrinol Metab (2012) 0.84
Mineralocorticoid receptor expression in human venous smooth muscle cells: a potential role for aldosterone signaling in vein graft arterialization. Am J Physiol Heart Circ Physiol (2011) 0.83
Role of ADAMs in endothelial cell permeability: cadherin shedding and leukocyte rolling. Circ Res (2008) 0.83
Gender differences in vascular smooth muscle reactivity to increases in extracellular sodium salt. Hypertension (2002) 0.83
Differential [Ca2+]i signaling of vasoconstriction in mesenteric microvessels of normal and reduced uterine perfusion pregnant rats. Am J Physiol Regul Integr Comp Physiol (2008) 0.82
Ca2+ antagonist-insensitive coronary smooth muscle contraction involves activation of epsilon-protein kinase C-dependent pathway. Am J Physiol Cell Physiol (2003) 0.82
Enhanced endothelin receptor type B-mediated vasodilation and underlying [Ca²⁺]i in mesenteric microvessels of pregnant rats. Br J Pharmacol (2013) 0.82
Elastase promotes aortic dilation by inhibiting Ca2+ influx into vascular smooth muscle. J Cardiovasc Pharmacol (2004) 0.82
EMMPRIN-mediated induction of uterine and vascular matrix metalloproteinases during pregnancy and in response to estrogen and progesterone. Biochem Pharmacol (2013) 0.81
Experimental benefits of sex hormones on vascular function and the outcome of hormone therapy in cardiovascular disease. Curr Cardiol Rev (2008) 0.81
Ca(2+)-dependent contraction by the saponoside escin in rat vena cava: implications in venotonic treatment of varicose veins. J Vasc Surg (2011) 0.81
Mechanisms of salt-sensitive hypertension: role of renal medullary inducible nitric oxide synthase. Am J Physiol Regul Integr Comp Physiol (2002) 0.80
Circulating and Vascular Bioactive Factors during Hypertension in Pregnancy. Curr Bioact Compd (2010) 0.80
Sex-related decrease in [Ca2+]i signaling and Ca2+-dependent contraction in inferior vena cava of female rat. Am J Physiol Regul Integr Comp Physiol (2009) 0.79
Low-salt diet enhances vascular reactivity and Ca(2+) entry in pregnant rats with normal and reduced uterine perfusion pressure. Hypertension (2002) 0.79
Vascular and cellular calcium in normal and hypertensive pregnancy. Curr Clin Pharmacol (2009) 0.78
Elastase-induced suppression of endothelin-mediated Ca2+ entry mechanisms of vascular contraction. Hypertension (2003) 0.78
Ca2+, calmodulin, and cyclins in vascular smooth muscle cell cycle. Circ Res (2006) 0.78
Sex hormones and vascular protection in pulmonary arterial hypertension. J Cardiovasc Pharmacol (2010) 0.77
Adaptive regulation of endothelin receptor type-A and type-B in vascular smooth muscle cells during pregnancy in rats. J Cell Physiol (2014) 0.77
Physiologic increases in extracellular sodium salt enhance coronary vasoconstriction and Ca2+ entry. J Cardiovasc Pharmacol (2002) 0.77
Functional adaptation of venous smooth muscle response to vasoconstriction in proximal, distal, and varix segments of varicose veins. J Vasc Surg (2010) 0.76
Endothelium-dependent nitric oxide and hyperpolarization-mediated venous relaxation pathways in rat inferior vena cava. J Vasc Surg (2011) 0.75
Research into Specific Modulators of Vascular Sex Hormone Receptors in the Management of Postmenopausal Cardiovascular Disease. Curr Hypertens Rev (2009) 0.75
Improved pulmonary vascular reactivity and decreased hypertrophic remodeling during nonhypercapnic acidosis in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2012) 0.75
Novel therapies and botanical and mechanical approaches for management of cardiovascular disease. Recent Pat Cardiovasc Drug Discov (2013) 0.75